Clinical trials: OS
Progress Free Survival (PFS) and Overall Survival (OS)
Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma
The aie of this clinical study is the safety and efficacy of combination therapy for HCC patients.
- Trial name
- NCT04393220
- Testing
- Bevacizumab Injection, Nivolumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Obesity, Sleep Restriction
Effects of Time of Sleep Restriction in Obesity
The purpose of this study is to determine the effect of different time of sleep restriction on control of food intake and metabolism of obese and normal subjects.
- Conditions
- Obesity, Sleep Restriction, Appetite Regulation, Eating
- Trial name
- NCT01259895
- Where
- Brazil
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Federal University of São Paulo
Foot Fusion
Augment® Bone Graft (Formerly GEM OS™1 Bone Graft) Compared to Autologous Bone Graft in Foot and Ankle Fusions
STUDY OBJECTIVES: Demonstrate equivalent clinical and radiologic outcomes to the "gold standard" (ABG) in a representative clinical model (hindfoot and ankle fusions) STUDY HYPOTHESIS: Augment® Bone Graft is an equivalent bone…
- Trial name
- NCT00583375
- Testing
- Augment® Bone Graft, Standard of Care
- Where
- 37 sites in United States, Canada
- Volunteers
- 414 people
- Sponsor
- BioMimetic Therapeutics
ORR,OS,PFS
Clinical Study of CD38\CS1 Chimeric Antigen Receptor T Cells in the Treatment of Refractory/Recurrent Multiple Myeloma
The investigators developed a dual-target CAR-T targeting CD38 and CS1. Previous experimental results showed that the investigators double-target CAR-T not only had a good killing effect on CD38/CS1 double-positive tumor cells…
- Trial name
- NCT06574958
- Testing
- CD38/CS1 injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Second Hospital of Shandong University
Non Small Cell Lung Carcinoma NSCLC
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
This is a randomized, open-label, multi-center Phase III study to determine the efficacy and safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of advanced NSCLC in patients who are epidermal…
- Trial name
- NCT03003962
- Testing
- Durvalumab (MEDI4736), Paclitaxel + carboplatin, Gemcitabine + cisplatin
- Where
- 92 sites in United States, Australia and 10 more
- Volunteers
- 669 people
- Sponsor
- AstraZeneca
PFS, OS
Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC
In recent years, immunotherapy has emerged as a form of treatment that can lead to robust responses in a subset of patients. PD-1 inhibitor plus chemotherapy showed prolonged survival in NSCLC by the study of KEYNOTE 024, KEYNOTE…
- Trial name
- NCT05267366
- Testing
- PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed
- Where
- China
- Volunteers
- 117 people
- Sponsor
- Qingdao Central Hospital
Circadian Disruption
Evaluation of Circadian OS Technology on Melatonin Suppression
Primary Objective: Evaluate how the Circadian OS iPad-based light intervention suppresses melatonin. This small pilot study is designed to validate the Circadian OS technology by testing physiological response using melatonin…
- Trial name
- NCT07095270
- Testing
- Circadian OS software
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Anesthesia Recovery
OS Anesthesia Followup of All Bariatric Procedures at One Hospital
Database registering demographic patient data, anesthesia and surgery information, post operative recovery and complications if any.
- Trial name
- NCT03200964
- Testing
- anesthesia given as required for surgical procedure
- Where
- Belgium
- Volunteers
- 20,000 people
- Sponsor
- AZ Sint-Jan AV
Tracheostomy Complication, Critical Illness
PUSH-IT Continuing Enteral Feeds for Tracheostomy
The goal of this clinical trial is to evaluate nutrition administration in the time around the tracheostomy in patients with breathing tubes.
- Conditions
- Tracheostomy Complication, Critical Illness, Nutritional Deficiency
- Trial name
- NCT05906472
- Testing
- Feeds continued, Feeds held
- Where
- 6 sites in United States
- Volunteers
- 200 people
- Sponsor
- State University of New York at Buffalo
Histologic Response (Tumor Necrosis Rate), Objective Response Rate for Neoadjuvant Chemotherapy, ORR
Epigenetic Biomarker for Osteosarcoma
hMe-Seal is a low-input whole-genome cell-free 5hmC sequencing method based on selective chemical labeling. It uses β-glucosyltransferase (βGT) to selectively label 5hmC with a biotin via an azide-modified glucose for pull-down…
- Conditions
- Histologic Response (Tumor Necrosis Rate), Objective Response Rate for Neoadjuvant Chemotherapy, ORR, Progression-free Survival, PFS, Overall Survival, OS
- Trial name
- NCT03336554
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Carcinoma, Non-Small-Cell Lung
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II…
- Trial name
- PACIFIC-4 (NCT03833154)
- Testing
- Durvalumab, (Osimertinib cohort, single-arm, open-label separate cohort)
- Where
- 209 sites in United States, Australia and 18 more
- Volunteers
- 724 people
- Sponsor
- AstraZeneca
Other Obstetric Trauma OS
Development of Mental Health Treatment for Obstetric Fistula Patients in Tanzania
The purpose of this study is to determine whether a mental health intervention for obstetric fistula patients in Tanzania improves primary outcomes (depression, PTSD and somatic symptoms) and secondary outcomes (coping, perceived…
- Trial name
- NCT01934075
- Testing
- Mental health treatment
- Where
- Tanzania
- Volunteers
- 60 people
- Sponsor
- Duke University
Pain
Comparison of Tramadol Orally Versus an Optimized Dose of Intravenous Tramadol for Postoperative Pain Relief in Ambulatory Surgery
The purpose of this study is to compare the administration of 1 unit dose of 50 mg tramadol perorally given in 3 unit dosages versus tramadol IV given in 3 unit dosage of 35 mg during the first 6 hours postoperatively and to…
- Trial name
- NCT00735748
- Testing
- Tramadol per os (Tradonal Odis® orodispersible tablets), Tramadol IV (Tradonal® IV)
- Where
- Belgium
- Volunteers
- 195 people
- Sponsor
- University Hospital, Ghent
Neuroendocrine Tumors
Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor
The study will be conducted to compare the safety and efficacy of Capecitabine Combined With Dacarbazine(CAPDTIC) and Capecitabine Combined Temozolomide(CAPTEM) in advanced or metastatic gastrointestinal pancreatic and esophageal…
- Trial name
- NCT03279601
- Testing
- Capecitabine, Dacarbazine, Capecitabine, Temozolomide
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Peking University
Glaucoma, Open-Angle
Valuation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) in Patients Affected by Primary Open Angle Glaucoma
This is a randomized, double blind study with competitive enrolment, aimed to enroll a total of 70 patients with a diagnosis of primary open angle glaucoma (POAG).
- Trial name
- NCT04038034
- Testing
- CoQ10- MINIACTIVES
- Where
- 2 sites in Italy
- Volunteers
- 70 people
- Sponsor
- VISUfarma SpA
Carcinoma, Non- Small Cell Lung
Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.
This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.
- Trial name
- MERMAID-2 (NCT04642469)
- Testing
- Durvalumab
- Where
- 115 sites in United States, Argentina and 23 more
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Duchenne Muscular Dystrophy (DMD)
To Compare the Pharmacokinetics Profiles of ISO 20, IBU 200 and IBU Plus ISO Combinations 200 + 20
This study will evaluate the pharmacokinetics plasma profile of 3 treatments: ISO 20, IBU 200 and IBU and ISO combinations (200 +20) given in single dose.
- Trial name
- ISOFEN1 (NCT01478022)
- Testing
- Isosorbide Dinitrate, Ibuprofen, Ibuprofen and Isosorbide Dinitrate combination
- Where
- Italy
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Parent Project, Italy
Heart Failure (HF)
A Study on the Correlation Between Cardiac-Cerebral Oxygenation Reserve and Cognitive Function Changes in Heart Failure Patients
At different stages of heart failure (HF), the cardiac and cerebral oxygen reserve exhibits varying degrees of decline due to chronic hypoxia and microvascular dysfunction caused by reduced cardiac output, leading to cognitive…
- Trial name
- NCT07485816
- Testing
- breathing training
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yan'an Affiliated Hospital of Kunming Medical University
Lung Diseases, Interstitial
A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)
This study is open to children and adolescents with interstitial lung disease (ILD) that causes lung fibrosis. This is a study for people who took part in a previous study called InPedILD (study 1199-0337) and for people who are…
- Trial name
- NCT05285982
- Testing
- Nintedanib (Ofev®)
- Where
- 28 sites in United States, Argentina and 15 more
- Volunteers
- 54 people
- Sponsor
- Boehringer Ingelheim
Lung Cancers, Lung Cancer, Non-Small Cell
Quality of Life as a Predictor of OS and PFS in Patients With Lung Cancer
By 2020, lung cancer continues leading the first cause of cancer mortality and the second most common type of cancer in the world.
- Trial name
- FACT-L_Pred (NCT06900283)
- Where
- Colombia
- Volunteers
- 320 people
- Sponsor
- Instituto Nacional de Cancerologia, Columbia